- Home
- EVG vs HURA Comparison
EVG vs HURA Comparison
Compare EVG & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EVG
Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Company Overview
Basic Information| Metric | EVG | HURA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.9M | 144.3M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | EVG | HURA |
|---|---|---|
| Price | $10.99 | $2.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 43.3K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.40 | $0.41 |
| 52 Week High | $11.45 | $3.99 |
Technical Indicators
Market Signals| Indicator | EVG | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 61.00 | 51.19 |
| Support Level | $10.90 | $2.26 |
| Resistance Level | $11.02 | $2.63 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 61.70 | 23.98 |
Price Performance
Historical ComparisonAbout EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.